Sanofi SNY
$47.04 +$0.13 (+0.28%)
Market closed · Nov 7, 9:10 am ET · Last extended-hours $46.12 -1.96%
Open$45.63
Prev close$46.91
Day range$45.58 – $47.16
Volume3.90M
Market cap$112.71B
P/E (TTM)24.1
Dividend yield4.99%
Earnings
Average move on report day±3.2%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+5.9%
Worst reaction-7.3%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 30 Oct 2026 | Pre Market | ±5.6% | +2.81% | Within range |
| 2026/Q2 | 30 Jul 2026 | Pre Market | ±4.2% | -4.37% | Bigger than priced |
| 2026/Q1 | 23 Apr 2026 | None | ±6.7% | +1.34% | Within range |
| 2025/Q4 | 29 Jan 2026 | Pre Market | ±6.8% | +0.94% | Within range |
| 2025/Q3 | 24 Oct 2025 | None | ±4.5% | +4.28% | Within range |
| 2025/Q2 | 31 Jul 2025 | None | ±5.8% | -7.33% | Bigger than priced |
| 2025/Q1 | 24 Apr 2025 | None | ±8.0% | +0.98% | Within range |
| 2024/Q4 | 30 Jan 2025 | Pre Market | ±6.4% | +3.84% | Within range |
| 2024/Q3 | 25 Oct 2024 | Pre Market | ±6.3% | +4.40% | Within range |
| 2024/Q2 | 25 Jul 2024 | None | ±7.8% | +3.71% | Within range |
| 2024/Q1 | 25 Apr 2024 | None | ±8.8% | +5.90% | Within range |
| 2023/Q4 | 1 Feb 2024 | Pre Market | ±7.1% | -2.99% | Within range |
| 2023/Q2 | 28 Jul 2023 | Pre Market | ±6.6% | -1.98% | Within range |
| 2023/Q1 | 27 Apr 2023 | None | ±7.3% | -0.23% | Within range |
| 2022/Q4 | 3 Feb 2023 | Pre Market | ±6.0% | -2.58% | Within range |
| 2022/Q3 | 28 Oct 2022 | None | ±7.0% | +3.54% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€15.23B+15.7% YoY
Operating profit€4.71B+24.3% YoY
Net profit€3.03B+7.9% YoY
Diluted EPS€1.26+9.6% YoY
Free cash flow€5.17B-0.1% YoY
Operating cash flow€3.87B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin73.4%
Operating margin21.6%
Net margin8.2%
Return on equity5.7%
Return on assets3.2%
Return on invested capital4.8%
Current ratio1.12
Liabilities / assets43.8%
Cash & investments€5.97B
Total debt€19.63B
Net cash (debt)-€13.66B
Free cash flow / sales16.5%
No comments yet — be the first to weigh in on SNY.
Sign in to join the discussion.